SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 ...

“I personally feel putting sun screen on your kids should be child abuse,” one UV truther wrote.

Sun Pharmaceuticals Ltd. and Cochin Shipyard Ltd. are among the key stocks picks for Gaurang Shah, head investment strategist ...

Sun Pharmaceutical Industries Ltd. closed 15.05% below its 52-week high of 1,960.20 rupees, which the company achieved on ...

Sun Pharma's clinical trial failure impacts SPARC stock, highlighting the challenges in derma-oncology research.

Sun Pharma shares are in focus after the company halted its Phase II clinical trial for SCD-044. Meanwhile, Zydus ...

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

The shares of Sun Pharma Advanced Research Company (SPARC) fell over 18 per cent on Wednesday, on BSE, on the announcement ...

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

Sun Pharma Advanced Research Company (SPARC) shares plummeted nearly 20% after its psoriasis drug, SCD-044, failed to meet primary endpoints in Phase 2 trials.

Sun Pharma disclosed that the drug did not meet primary endpoints in either study and as a result, the development of the SCD ...